Shionogi & Co Ltd

Shionogi & Co Ltd, established in 1878, is a prominent Japanese pharmaceutical company operating within the Healthcare and Pharmaceuticals sectors. Headquartered in Osaka, Japan, the company is dedicated to developing innovative treatments that significantly improve patient lives globally. Its mission centers on addressing critical global health challenges through pioneering research and development.

The company has established itself as a leader in novel therapies for infectious diseases, including a strong focus on antibiotics, HIV, influenza, and emerging viral threats such as COVID-19. Shionogi employs a robust R&D strategy, combining internal expertise with strategic collaborations with industry partners, government agencies, biotech firms, and academic institutions. This approach accelerates the delivery of scientific programs and brings essential therapies to patients with urgency. With an employee range of 1,000-5,000 employees and operations across 10 locations, the company is positioned for global impact. Meet Shionogi & Co Ltd's team to understand their leadership driving these initiatives.

Shionogi & Co Ltd generates substantial revenue, reporting $1.7B, underscoring its significant market presence. The company operates in a competitive landscape, facing entities such as PRA Health Sciences and Medpace. Its URL is www.shionogi.com, serving as a gateway to its extensive product pipeline and corporate information. The company's commitment to innovation and patient well-being drives its ongoing efforts in drug discovery and commercialization.